Patents by Inventor Andreas Raue

Andreas Raue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-OX40 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF
    Publication number: 20240317874
    Abstract: Provided is a novel anti-OX40 antibody, including the compositions of anti-OX40 antibody, a polynucleotide encoding the anti-OX40 antibody, methods of preparing the anti-OX40 antibody, and methods of using the anti-OX40 antibody.
    Type: Application
    Filed: June 28, 2022
    Publication date: September 26, 2024
    Inventors: Francisco Adrian, Liang Schweizer, Qian Zhang, Yun-Yueh Lu, Andreas Raue
  • PREDICTIVE RESPONSE BIOMARKER DISCOVERY PROCESS
    Publication number: 20230160009
    Abstract: The invention described herein provides a method to identify predictive response biomarkers (PRBs) for a treatment regimen. The PRBs can be used to identify suitable or unsuitable) patient population for the treatment regimen.
    Type: Application
    Filed: June 17, 2021
    Publication date: May 25, 2023
    Applicant: HIFIBIO (HK) LIMITED
    Inventors: Liang Schweizer, Andreas Raue, Dean Sung-Ling Lee
  • ANTI-OX40 ANTIBODY AND USE THEREOF
    Publication number: 20230061604
    Abstract: Provided are an anti-OX40 antibody, a composition including the anti-OX40 antibody, a nucleic acid encoding the anti-OX40 antibody, a method for preparing the anti-OX40 antibody, and a use of the anti-OX40 antibody.
    Type: Application
    Filed: December 28, 2020
    Publication date: March 2, 2023
    Inventors: Hongkai Zhang, Yuan Wang, Yun-Yueh Lu, Yuqiang Shen, Nicola Arturo Aldo Beltraminelli, Liang Schweizer, Francisco Adrian, Klaus Andreas Raue, Qian Zhang, Jinping Gan
  • ANTI-TNFR2 ANTIBODIES AND USES THEREOF
    Publication number: 20210371537
    Abstract: Anti-TNFR2 antibodies which bind to particular human TNFR2 epitopes, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer are disclosed.
    Type: Application
    Filed: September 18, 2019
    Publication date: December 2, 2021
    Inventors: Eric M. TAM, Marco MUDA, Klaus Andreas RAUE, Vinodh B. KURELLA, Daryl Clark DRUMMOND, Ross Bane FULTON, Fabien DEPIS, Anne-Sophie DUGAST, Jian TANG, Sandeep KUMAR
  • METHODS FOR THE PREDICTION OF A PERSONALIZED ESA-DOSE IN THE TREATMENT OF ANEMIA
    Publication number: 20210093696
    Abstract: An integrative pharmacokinetic/pharmacodynamics (PK/PD) ESA-EpoR mathematical model calculates the binding behavior of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.
    Type: Application
    Filed: August 28, 2020
    Publication date: April 1, 2021
    Inventors: Agustin Rodriguez Gonzalez, Marcel Schilling, Ursula Klingmueller, Andreas Raue, Max Schelker, Jens Timmer, Michael Jarsch, Bernhard Steiert
  • Methods for the prediction of a personalized ESA-dose in the treatment of anemia
    Patent number: 10796799
    Abstract: An integrative pharmacokinetic/pharmacodynamics (PK/PD) ESA-EpoR mathematical model calculates the binding behavior of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: October 6, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS, ALBERT-LUDWIGS-UNIVERSITAT FREIBURG
    Inventors: Agustin Rodriguez Gonzalez, Marcel Schilling, Ursula Klingmueller, Andreas Raue, Max Schelker, Jens Timmer, Michael Jarsch, Bernhard Steiert
  • Methods For The Prediction Of A Personalized ESA-Dose In The Treatment Of Anemia
    Publication number: 20170128532
    Abstract: The present invention pertains to the use of an Integrative pharmacokinetic/pharmacodynamic (PK/PD) ESA-EpoR mathematical model for calculating the binding behaviour of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.
    Type: Application
    Filed: June 18, 2015
    Publication date: May 11, 2017
    Inventors: Augustin Rodriguez, Marcel Schilling, Ursula Kling-Muller, Andreas Raue, Max Schelker, Jens Timmer, Michael Jarsch, Bernhard Steiert